Type 2 diabetic patients with left ventricular diastolic dysfunction
Conditions
Interventions
Sponsors
Cardiovascular Dysfunction Study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1, T2DM patients those who have been treated with the diabetic therapy and whose blood glucose has not been sufficiently controlled 2, The patients with left ventricular diastolic dysfunction LVEF>50% e'< 8 cm/s and/or E/e'>15 3, Obtaining written informed consent
Exclusion criteria
Exclusion criteria: 1, The patient under insulin treatment 2, The patient under alpha-GI or Gulinide treatment 3, Severe ketosis, diabetic coma, or precoma within the past six months 4, Severe infectious disease, pre/ post operation or serious injury 5, Type 1 diabetes mellitus 6, Insufficiently controlled diabetes mellitus (HbA1c >= 9.0% ) 7, Insufficiently controlled hypertension (SBP>=160mmHg) 8, Myocardial infarction or stroke within 6 months before recruiting 9, LV hypertrophy (LV wall thickness > 13mm) 10, The patient with atrial fibrillation 11, The patient with significant valvular disease 12, Women who are pregnant, possibly pregnant, or are breastfeeding 13, Mild renal dysfunction (sCr>=1.5 mg/dl) 14, Hypersensitivity or allergy to sitagliptin and voglibose 15, Patients who are determined by the investigators to be unsuitable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in e' and e'/E after 24 weeks | — |
Countries
Japan
Contacts
Public ContactNaoko Fujimoto
Cardiovascular Dysfunction Study group Research Secretariat Office
Outcome results
None listed